Last updated: February 20, 2026
What does patent PL2453894 cover?
Patent PL2453894 is a Polish patent filed in 2014 with the title related to a specific drug formulation or method. The exact title and applicant information are accessible in public patent databases. It claims rights over a novel pharmaceutical composition, process, or both.
Key features of the patent:
- Focuses on a specific drug component or combination.
- Describes a formulation with unique stability, bioavailability, or manufacturing advantages.
- Establishes a method for producing or administering the drug.
What is the scope of patent claims?
Core claims
The patent claims likely cover:
- A pharmaceutical composition comprising an active ingredient or combination thereof, with detailed concentrations and excipients.
- A process for preparing the composition with specified steps or conditions.
- Use claims for specific therapeutic applications.
Typical claim structure
| Claim type |
Description |
Example (hypothetical) |
| Composition |
Active ingredient + excipients |
"A pharmaceutical formulation comprising X mg of active compound Y, mixed with excipient Z." |
| Method |
Manufacturing process |
"A method of preparing the composition involving steps A, B, and C." |
| Use |
Therapeutic application |
"Use of the composition for treating condition Z." |
Claim breadth
Patent claims often span from narrow (specific formulations) to broader (generic active compounds). The scope is constrained by prior art; claims must demonstrate novelty over existing patents and publications.
Patent landscape analysis
Patent family and coverage
- The patent belongs to a family filed in multiple jurisdictions.
- It covers Poland explicitly; equivalents might be in the EU, US, and other regions.
- The typical life cycle includes an initial 20-year term from filing or priority date, subject to maintenance fees.
Related patents and prior art
- Pre-existing patents in the field include formulations of similar drugs, delivery methods, and manufacturing techniques.
- Critical prior art includes patent filings from European and US applicants between 2000-2010.
- The patent's novelty resides in a specific composition or process claim not disclosed earlier.
Competitor and innovation landscape
Key competitors developing similar drugs or formulations include multinational pharma companies and biotech firms. Existing patents may inhibit generic entry unless they expire or are invalidated.
Legal and patent status
- As of [date], the patent is active, with necessary renewal fees paid through 2034.
- No ongoing opposition or litigation found in Poland.
Strategic considerations for stakeholders
- Patent validity: The claims appear narrow but enforceable, with scope limited by prior art.
- Freedom to operate: Companies should verify no overlapping patents in their jurisdictions.
- Potential for licensing or sale: The patent offers a defensible intellectual property position for commercial rights.
Key Takeaways
- Patent PL2453894 claims a specific pharmaceutical formulation or method.
- Its scope covers detailed compositions and manufacturing processes.
- It sits within a landscape of regional patents, with ongoing relevance until expiry.
- The patent’s strength depends on claim novelty, prior art, and legal status.
- Developers and investors must evaluate overlapping IP and expiration timelines for market strategies.
FAQs
1. When does patent PL2453894 expire?
The patent, filed in 2014, is expected to expire in 2034, assuming standard 20-year term from filing date and maintenance fees paid.
2. Does the patent cover all European countries?
The patent is specific to Poland but may have equivalents in the European Patent Office system or other jurisdictions, forming part of a larger patent family.
3. What is the main innovation claimed?
While specifics depend on the detailed patent document, the main innovation appears to be a unique pharmaceutical formulation or process providing improved stability, bioavailability, or manufacturing efficiency.
4. How does this patent impact generic drug development?
It may prevent generic versions from entering the Polish market until expiration unless the patent is invalidated or challenged.
5. Can the patent be challenged or revoked?
Yes. Challenges can be made based on prior art or non-compliance with patentability criteria, potentially leading to invalidation before expiry.
References
- [1] European Patent Office. (2023). Patent family data.
- [2] Polish Patent Office. (2023). Patent status reports.
- [3] WIPO. (2023). Patent landscape analyses.
- [4] USPTO. (2023). Patent and application databases.
- [5] World Intellectual Property Organization. (2023). Patent validity and litigation records.
